following an abbreviated submission:
buprenorphine/naloxone (Zubsolv®) is accepted for restricted use within NHSScotland.
Indication under review: substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.
SMC restriction: for use in patients for whom methadone is not suitable.
Buprenorphine/naloxone (Zubsolv®) is available at a slightly lower cost when compared to another buprenorphine/naloxone combination product.
Prescribers should be aware that buprenorphine preparations are not interchangeable.
Download detailed advice637KB (PDF)
Medicine details
- Medicine name:
- buprenorphine and naloxone (Zubsolv)
- SMC ID:
- SMC2123
- Indication:
Substitution treatment for opioid drug dependence.
- Pharmaceutical company
- Accord Healthcare
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 07 November 2022